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Objective: to identify the different types of morphological alterations from lipodystrophy 
syndrome (LS) in outpatients and relate them to the therapeutic regimen used. Method: a 
cross-sectional study which recruited 60 patients with HIV and LS and 79 without LS, who 
consented to interview and data collection from their medical notes. Results: the region 
most affected by lipoatrophy was the face; by lipohypertrophy, the abdomen, and by the 
mixed form, the alterations to the abdomen, face, and upper and lower limbs. Conclusion: 
among the therapeutic regimens, that comprised of zidovudine, lamivudine and efavirenz 
seemed to protect against LS. Nursing can act in the early identification of the changes, as 
well as providing guidance and support for patients affected by the changes in their body 
image.
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Alterações corporais: terapia antirretroviral e síndrome da lipodistrofia 
em pessoas vivendo com HIV/AIDS
Objetivo: identificar os diferentes tipos de alterações morfológicas da síndrome da 
lipodistrofia (SL) em pacientes dos atendimentos ambulatoriais e relacioná-las ao 
esquema terapêutico utilizado. Método: estudo transversal, para o qual foram recrutados 
60 pacientes com HIV e  SL e 79 sem a SL, que consentiram entrevista e coleta de dados 
em prontuário. Resultados: a região mais acometida pela lipoatrofia foi a face; pela 
lipo-hipertrofia o abdome e pela forma mista as alterações em abdome, face, membros 
superiores e inferiores. Conclusão: dentre os esquemas terapêuticos, o composto pela 
zidovudina, lamivudina e efavirenz pareceu proteger contra a SL. A enfermagem pode 
atuar na identificação precoce das alterações, além de fornecer orientações e apoio aos 
pacientes acometidos pelas mudanças na imagem corporal.
Descritores: HIV-1; Terapia Anti-Retroviral de Alta Atividade; Síndrome de Lipodistrofia 
Associada ao HIV; Enfermagem.
Alteraciones corporales: terapia antirretroviral y síndrome de la 
lipodistrofia en personas que viven con VIH/SIDA
Objetivo: identificar los diferentes tipos de alteraciones morfológicas del Síndrome 
de la lipodistrofia (SL) en pacientes de los servicios de ambulatorio y relacionarlas al 
esquema terapéutico utilizado. Método: estudio transversal en lo que fueron reclutados 
60 pacientes con VIH y la SL y 79 sin la SL, que consintieron entrevista y recogida de 
datos en prontuario. Resultados: la región más acometida por la lipoatrofia fue la cara; 
por la lipohipertrofia el Abdomen y por la forma mixta las alteraciones en Abdomen, 
cara, miembros superiores e inferiores. Conclusión: entre los esquemas terapéuticos, 
el compuesto por la zidovudina, lamivudina y efavirenz pareció proteger contra la SL. 
La enfermería puede actuar en la identificación precoz de las alteraciones, además de 
suministrar orientaciones y apoyo a los pacientes acometidos por los cambios en la 
imagen corporal.
Descriptores: VIH-1; Terapia Antirretroviral Altamente Activa; Síndrome de Lipodistrofia 
Asociada a VIH; Enfermería.
Introduction
Lipodystrophy Syndrome (LS) is currently 
one of the most worrying problems resulting from 
antiretroviral therapy (ARVT) for combatting the human 
immunodeficiency virus (HIV). Its pathogenicity still 
not totally understood, it is observed in therapeutic 
regimens which include the antiretrovirals (ARV) in the 
classes of the Nucleoside Analog Reverse-Transcriptase 
Inhibitors (NARTI) and the Protease Inhibitors (PI)(1-2).
It is characterized principally by alterations in the 
distribution of body fat, such as the loss of peripheral 
subcutaneous tissue and increase of central fat, and 
by metabolic disorders such as dyslipidemia, insulin 
resistance and abnormal glucose homeostasis, which 
may contribute to the development of cardiovascular 
illnesses and diabetes mellitus(3-4).
Morphological abnormalities resulting from 
alterations in the distribution of fat are manifested in 
various ways. Lipoatrophy (loss of adipose tissue) 
is noted on the face, buttocks and limbs, in which 
the venous circulation becomes more evident. Fat 
accumulation (lipohypertrophy) is seen in the central 
abdominal region, in addition to deposits in the breasts 
and dorsocervical region, also called the “buffalo’s 
hump”(5-6).  
Fat loss and accumulation can occur simultaneously 
– in different regions of the body – in the same individual. 
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This is called the mixed form. About 50% of the patients 
receiving antiretroviral therapy are affected by body 
changes resulting from LS(7-8). Among Brazilian patients, 
the prevalence described was of 55%(9). Despite the 
great success of drug therapy in reducing the patients’ 
morbidity and mortality rates(10), the effects of LS – in 
particular, those which cause alterations in body image 
– contribute to the appearance of stigma, problems 
in social activities and alterations in sexuality, among 
others, impacting on quality of life(11-12).
Nursing has been developing various studies 
concerning the effects of LS on patients, from identifying 
their perceptions about changes in appearance(13), to testing 
interventions which help them to face these(14). The 
periodicals in the area, however, do not provide detailed 
evidence on discriminating between the morphological 
abnormalities by anatomical region, correlated with the 
ARVT used. Providing nursing care for the HIV patient 
requires varying skills of  health professionals, as they 
are dealing with a client group which presents a range 
of simultaneous needs. Particularly in relation to drug 
therapy, the nurse has the mission of informing the client 
about its benefits and the need for good compliance, as 
well as the possible side-effects and ways of controlling 
them, such that the patient feels safe in undergoing the 
treatment(15).
Thus, this study aimed to identify the different types 
of morphological alterations from LS present in outpatients 
and relate them to the therapeutic regimen being used, so 
as to provide support for nursing professionals to be able to 
promote specialized care for this population’s needs.
Method
This is a cross-sectional, comparative, descriptive 
study, carried out through a questionnaire with 14 
closed questions, which included demographic data, 
current conditions of opportunistic infection, the case 
history of the HIV infection, ARV medication being 
used, and clinic-laboratory and somatometric data. The 
questionnaire was developed by the study group, based 
on the literature available, and applied by the same group 
individually to each patient, before or after their routine 
medical consultation, in a private room. Laboratory 
data, as well as data of the ARV therapeutic regimens, 
were taken from the patients’ medical notes. The study 
was approved by the Research Ethics Committee of the 
Clinical Hospital of the Faculty of Medicine of Ribeirão 
Preto (process nº 5761/2007) and all the participants 
signed the Terms of Free and Informed Consent. 
Study population
Sixty patients with LS were selected at the 
Dyslipidemia Outpatient Department in the Special 
Unit for Treatment of Infectious Diseases at the Clinical 
Hospital of the Faculty of Medicine of Ribeirão Preto, 
part of the University of São Paulo, which exclusively 
attends patients with HIV-1, and is a regional center of 
excellence for this type of care. The study’s inclusion 
criteria were: positive serology for HIV-1, age between 
18 and 65 years, treatment with ARV for a minimum of 18 
months and morphological alterations related to LS. The 
morphological alterations of the patients with LS were 
identified based on agreement between the patients’ 
accounts, medical observations, and observations made 
by the researchers about body shape alterations.
For the comparison group, the researchers selected 
79 patients with positive serology for HIV-1, aged 
between 18 and 65, receiving ARV treatment for a 
minimum of 18 months and with no reference for any 
type of body change related to LS. 
Statistical analysis
The results were analyzed using Fisher’s exact 
test, with the help of the GraphPad InStat 3.01 program. 
Associations with a probability of below 5% (p<0.05) were 
considered.
Results
Of the 60 patients with LS selected for the study, 
40 (67%) were male and 20 (33%) female; 45 (75%) 
were Caucasian, 08 (13.33%) were Afro-Brazilian and 
7 (11.66%) were mixed-race. The participants’ average 
age was 43.08±7.9 years. The time since diagnosis 
of infection with HIV-1 varied from 3.5 years to 16 
years (average = 9.22±2.81 years) and the duration 
of treatment with antiretrovirals varied from 2 to 13 
years (average = 7.5±2.70 years). In relation to the 
quantification of HIV-1 viral RNA (viral load), in 31 
patients (51.66%) it was undetectable. 
Of the 79 patients selected for the study who 
were characterized as non-carriers of lipodystrophy 
syndrome, 50 (63.29%) were male and 29 (36.70%) 
female; 60 (75.9%) were Caucasian, 08 (10.1%) Afro-
Brazilians and 11 (13.9%) of mixed race. The length 
of time since diagnosis with infection by HIV-1 varied 
from 2 to 20 years (average = 7.37±4.05 years) and the 
duration of antiretroviral treatment from 1.5 to 15 years 
(average = 5.46±2.74 years). In relation to viral load, 
47 (59.49%) of the patients presented one which was 
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undetectable. The lipidogram values of the patients with 
and without LS are shown in Table 1.
In the analysis of the most-affected body regions, 
the researchers verified the therapeutic regimens 
used.  Table 3 shows the comparison of the therapeutic 
regimens most used by the patients with and without 
LS. Table 4 shows the comparison of each retroviral 
medication used by the patients with and without LS.
Variables With LS(n = 60)
Without LS
(n = 79)
Cholesterol (mg/dL)  199.61 ± 57.68 160,05 ± 25,63
HDL cholesterol (mg/dL) 38.3 ± 12.54 41.21 ± 11.01
LDL cholesterol (mg/dL) 113.47 ± 49.54 96.54 ± 22.52
Triglycerides (mg/dL) 303.1 ± 256.57 100.76 ± 34.87
Table 1 – Lipidogram values of the patients with HIV-1, 
with and without LS
Reference values: Total cholesterol: < 200 mg/dL; HDL: >35 mg/dL; LDL: 
< 130 mg/dL; Triglycerides: < 150 mg/dL.
Regarding morphological abnormalities, 23 
patients (38.33%) showed signs of lipoatrophy, 9 (15%) 
only showed signs of fat accumulation and 28 patients 
(46.66%) presented the mixed form. The stratifications, 
in accordance to the abnormalities’ localization on the 
body, are presented in Table 2.  
Variables n = 60 %
Lipoatrophy
Face 15 25.0
Face, UL 1 1.6
Face, LL 1 1.6
Face, UL, LL 5 8.3
UL, LL 1 1.6
Lipohypertrophy
Abdomen 5 8.3
Abdomen, breast 2 3.3
Abdomen, dorsocervical 1 1.6
Abdomen, thorax 1 1.6
Mixed form
Face, breast 1 1.6
Face, dorsocervical 1 1.6
Abdomen, UL, LL 3 5.0
Abdomen, UL, buttocks, breast 1 1.6
Abdomen, buttocks, prominent veins 1 1.6
Abdomem, face 4 6.6
Abdomen, face, dorsocervical 1 1.6
Abdomen, face, UL 2 3.3
Abdomen, face, UL, LL 6 10.0
Abdomen, face, UL, LL, prominent veins 1 1.6
Abdomen, face, UL, LL, dorsocervical 1 1.6
Abdomen, face, buttocks 1 1.6
Abdomen, face, buttocks, prominent veins 1 1.6
Abdomen, face, buttocks, UL, LL 2 3.3
Abdomen, face, buttocks, UL, LL, dorsocervical 1 1.6
Abdomen, face, buttocks, UL, LL, prominent 
veins, breast 1 1.6
Table 2 – LS morphological abnormalities’ localization, 
according to body region
UL: upper limbs; LL: lower limbs.
Therapeutic regimen With LS(n = 18)
Without LS
(n = 58) P
AZT, 3TC, EFZ 05 36 0.0149
AZT, 3TC, NVP 02 06 1.0000
TDF, 3TC, NVP 02 0 0.0537
TDF, 3TC, EFZ, LPV/r 02 01 0.1378
D4T, 3TC, EFZ 04 03 0.0502
AZT, 3TC, LPV/r 01 02 0.5611
AZT, 3TC, RTV, ATV 0 02 1.0000
AZT, 3TC, NFV 0 03 1.0000
TDF, 3TC, RTV, ATV 01 03 1.0000
TDF, 3TC, LPV/r 01 02 0.5611
Table 3 – Comparison of the therapeutic regimens most 
used by the patients with and without LS
Nucleoside Analog Reverse Transcriptase Inhibitors (NARTI): AZT: 
Zidovudine; d4T: Stavudine; 3TC: Lamivudine; TDF: Tenofovir.
Non-nucleoside reverse transcriptase inhibitor (NNRTI): EFZ: Efavirenz; 
NVP: Nevirapine.
Protease inhibitor (PI): ATV: Atazanavir; NFV: Nelfinavir; RTV: Ritonavir; 
LPV/r: (Lopinavir/Ritonavir).
Statistically-significant data is in bold type.
Table 4 – Comparison of the action of each retroviral 
medication used by patients with and without LS
Antiretroviral With LS(n = 60)
Without LS
(n = 79) P
AZT 23 58 <0.0001
3TC 47 74 0.0103
TDF 19 13 0.0427
d4T 17 11 0.0536
ddI 10 04 0.0432
ABC 02 0 0.1845
NVP 06 10 0.7899
EFV 34 46 0.8643
LPV/r 14 10 0.1160
ATV 07 10 1.0000
RTV 12 09 0.2314
NFV 01 06 0.1402
SQV 04 02 0.4025
APV 02 0 0.1845
T-20 02 0 0.1845
Nucleoside analog reverse transcriptase inhibitors (NARTI): AZT: 
Zidovudine; ddI: Didanosine; ABC: Abacavir; d4T: Stavudine; 3TC: 
Lamivudine; TDF: Tenofovir.
Non-nucleoside reverse transcriptase inhibitor (NNRTI): EFZ: Efavirenz; 
NVP: Nevirapine.
Protease inhibitor (PI): ATV: Atazanavir; NFV: Nelfinavir; RTV: Ritonavir; 
SQV: Saquinavir; APV: Amprenavir; LPV/r: (Lopinavir/Ritonavir).
Fusion inhibitor (FI): T- 20: Enfuvirtide.
Statistically-significant data is in bold type.
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Discussion
The pathogenicity of LS has been under study for 
over 10 years, and various factors have been identified 
as contributing to its development, such as gender, age, 
duration and seriousness of infection with HIV-1(2,16), and 
the use of antiretroviral therapy(1-2), in addition to the 
influence of the inflammatory cytokine genes in patients 
with LS on ARVT(17).
Of the alterations caused by LS, those which 
cause great difficulties for the patients are the 
alterations in body harmony negatively impacting on 
their daily activities(11). In our study, the morphological 
abnormalities were described in 23 patients (38.33%) 
in the form of lipoatrophy, in 9 (15%) as signs of fat 
accumulation, and 28 patients (46.66%) in the mixed 
form. These prevalencies are close to a description 
which evaluated a sample of 1,348 patients(8).
Lipoatrophy has been showed to be more frequent 
than lipohypertrophy(18) and the face is the most-
affected body region, followed by the lower limbs, the 
buttocks, and the upper limbs(18). In the present study’s 
stratification, the face was the most-affected region, 
although the authors did not identify differences of 
prevalence between the upper limbs (MMSS) and the 
lower limbs (MMII), neither lipoatrophy exclusive to the 
buttocks, which was only perceived in the mixed form of 
LS. In relation to lipohypertrophy, the abdomen was the 
most-affected body region, in line with other studies(2,8), 
followed by the breast, dorsocervical region and thorax. 
The most found mixed form was shown by the presence 
of lipohypertrophy of the abdomen and atrophy of the 
face, upper limbs and lower limbs.  
Retroviral drugs’ association with LS is incontestable 
and was described a long time ago. In view of this, an 
analysis was undertaken of the therapeutic combinations 
most used by the two groups of patients studied – with 
and without LS (Table 3). Thus, the therapeutic regimen 
made up by the combination of Zidovudine + Lamivudine 
+ Efavirenz (AZT + 3TC + EFZ) was shown to be a 
protector against LS (p=0.0149). A study carried out 
with 100 patients who received this same therapeutic 
combination for 48 weeks and who were later evaluated 
using imaging exams – computerized tomography and 
DEXA – dual X-ray absorptiometry – confirms that this 
therapeutic regimen is not associated with significant 
morphological changes, as it resulted in a minimal and 
modest fat accumulation(19).
The influence of NARTI class medications in the 
development of LS is predominantly reported through 
the use of Stavudine (d4T)(20) and of AZT, in lower 
intensity(21).
When the authors analyzed each antiretroviral 
drug in isolation (Table 4), two drugs from the NARTI 
class - AZT and Lamivudine (3TC) – seemed to suggest 
protection against the development of LS (p<0.0001 
and p=0.0103, respectively). However, the authors 
emphasize that a better investigation is necessary, 
including a thorough analysis of the therapeutic 
combinations used. In addition, consistent information 
was not found on the influence of 3TC on its own in the 
development of LS. Furthermore, there is a report of the 
combination of these two drugs in the development of 
morphological changes(22).
According to the present study’s data, a further two 
drugs in this class - Tenofovir (TDF) and Didanosine (ddI) 
seem to contribute to the development of LS (p=0.0427 
and p=0.0432, respectively). The information on the 
role of ddI in LS are conflicting: one study states that 
this drug is independently associated with LS(23) and 
another, that the use of ddI is significantly associated 
with the depletion of mitochondrial DNA in the adipose 
tissue of patients with peripheral lipoatrophy, and 
that this may be reverted with discontinuation of 
use(24).  However, another study states that ddI does 
not contribute to peripheral lipoatrophy(25). In relation 
to TDF, in contrast to what the present study’s authors 
found, it seems there is a consensus in the literature 
that the substitution of d4T with TDF minimizes the 
risk of developing LS(20), improving the recuperation of 
peripheral adipose tissue and in this way contributing to 
the reversal of lipoatrophy(26). 
Despite the PI class being widely related to LS(5), the 
authors did not determine influences of these medications 
in the present study.  
New antiretroviral drugs are being developed 
and used in the treatment against infection by HIV, 
and further studies will be necessary on their adverse 
effects over time.  The authors understand that the 
fact that the study does not determine the exact 
length of treatment for each type of antiretroviral 
and/or therapeutic regimen – which can interfere in 
the development of LS – is a limitation on the study. 
However, the authors can provide support for specialized 
nursing care for this client group, in regard to monitor 
their therapeutic regimens; identifying and intervening 
in both morphological changes and changes in their lipid 
profile, and providing psychosocial support in the face of 
changes in body image.
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Conclusion
With this study, the authors conclude that the 
region most affected by lipoatrophy was the face, 
the region most affected by lipohypertrophy was the 
abdomen, and the region most affected by the mixed 
form was a complex of changes present in the abdomen, 
face, MMSS and MMII. Of the therapeutic regimens most 
used by the patients (both with and without LS), that 
composed of AZT+3TC+EFZ seemed to protect against 
the development of LS. However, further studies are 
necessary, particularly in relation to the drugs AZT, 
3TC, TDF and ddI in the development of LS. In relation 
to nursing care, it is possible to identify the need for 
knowledge of each drug’s effects, so as to achieve 
early interventions which avoid the changes in body 
image, as well as the consequences of this. Working 
in a participative way in the treatment the nurse will 
help the patient to deal with the difficulties related to 
self-esteem, as well as contributing to a reduced rate of 
abandonment of the therapy.
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